Therefore, to identify the differences between BRCA1/2-MUT BC and BRCA1/2 wild-type (BRCA1/2-WT) BC, we used consensus WGCNA, an improved analysis method which was conducted in our study using a slightly different R package code on the basis of the general principles of WGCNA, thereby perform the comparison of the effect of modules on associated clinical traits between mutant and WT cancers. The gene discussed is BRCA1; the disease is breast cancer.